Step Therapy for Wegovy and Zepbound: How It Works and How to Get Through It

Step therapy — sometimes called "fail first" — is the requirement by most insurance plans that you document failure with cheaper drugs before they will pay for Wegovy or Zepbound. It delays access, adds documentation burden, and is the primary reason PA for GLP-1s takes weeks rather than days.

Understanding exactly what your plan requires — before the first submission, not after the first denial — is what separates a 3-week approval from a 3-month one.

Why step therapy exists for GLP-1s

GLP-1 drugs cost insurers $800–1,500/month at retail. Plans use step therapy to ensure that lower-cost interventions (some as cheap as $4/month generic) are documented before committing to that spend. This is standard for specialty drugs — it is not specific to GLP-1s.

For obesity-labelled GLP-1s (Wegovy, Zepbound), the typical step therapy sequence:

1. Behavioural counselling or supervised weight-loss programme — some plans require documentation of participation in a programme (3–6 months)
2. One or more pharmacological alternatives — common candidates:
   • Metformin (off-label for obesity, standard T2D drug, ~$4/month generic)
   • Phentermine (controlled stimulant, 30-day prescriptions, ~$15/month generic)
   • Topiramate or phentermine/topiramate (Qsymia) — some plans
   • Orlistat (lipase inhibitor, OTC or Rx) — some plans
   • Bupropion-naltrexone (Contrave) — some plans

Your specific plan's step therapy requirements are in the coverage criteria document or formulary management policy. This is a long PDF that your insurer's member services department can provide, or that your prescriber can request from the plan.

What counts as failure

The definition of failure varies by plan, but the most common standard:

Efficacy failure: Prescribed drug at therapeutic dose for ≥90 days with <5% body weight loss documented. The documentation required: start weight, end-of-trial weight, dose prescribed, dates, and a clinical note explaining the trial outcome.

Tolerability failure: Side effects that caused discontinuation before 90 days, with documentation of the adverse effect in the medical record.

Contraindication: A clinical reason the required drug is contraindicated for your specific situation — e.g., phentermine is generally contraindicated in patients with cardiovascular disease, hyperthyroidism, or history of drug abuse.

Prior failure before current plan enrollment: If you tried the required drug with a previous provider or before joining your current plan, some insurers accept pharmacy claims data or a prior medical record as evidence. Others require a new documented trial under the current plan. This is worth clarifying with your insurer before re-starting a drug you've already tried.

How to document proactively

The single most effective PA strategy is complete documentation before the first submission, not correcting gaps after a denial.

Before the PA submission, your prescriber's documentation should include:

1. BMI and qualifying condition: Current weight, height, BMI ≥30 (or ≥27 with documented comorbidity — hypertension, T2D, obstructive sleep apnoea, cardiovascular disease)
2. Step therapy drugs tried: Each drug, dose, duration of trial, weight at start and end, reason for stopping (efficacy failure, side effects, or contraindication)
3. Medical necessity letter: A narrative from the prescriber explaining why Wegovy or Zepbound is medically necessary for this patient given the clinical picture
4. Relevant comorbidities: Conditions that make GLP-1 therapy clinically appropriate — particularly if there is a cardiovascular indication (SELECT trial data supports semaglutide 2.4 mg for CV risk reduction in patients with established CVD)
5. Prior programme participation: Documentation of any supervised weight-loss programme participation if required by the plan

What the insurer is looking for: A clinical story that follows the required steps, with supporting dates and clinical evidence. The PA submission that fails first and then is appealed almost always fails due to missing documentation — a trial period without recorded weights, or a drug listed without dates.

The appeals process

If the initial PA is denied, you have appeal rights. The first level of appeal is typically a clinical review by a physician medical director at the insurer (often faster than the initial review — 72 hours for urgent, 30 days for standard). The second level is an external independent review.

Strong appeal grounds for GLP-1 PA:

• Contraindication: Document that a required step drug is contraindicated for your specific clinical situation with citation to relevant prescribing information
• Prior adequate trial: Evidence (pharmacy records, prior medical records) of a prior trial that meets the plan's definition
• Clinical urgency: Documentation of comorbidities (class 3 obesity, T2D, CVD) that make delay medically harmful
• Step therapy override law: If your state has a step therapy override statute and your plan is fully-insured, cite the specific statute

The prior authorisation appeal guide covers the full appeals process including letter templates and regulatory framework.

State-level protections

Many states have enacted step therapy override laws that require insurers to grant exceptions when:

• The required drug has been tried and failed previously
• The required drug is contraindicated based on clinical judgment
• The required drug would negatively impact adherence to another treatment
• The prescriber determines the step therapy protocol is not in the patient's clinical interest

These protections apply to fully-insured plans (where the employer buys a policy from an insurer regulated by the state). They do not apply to self-funded ERISA plans (where large employers self-insure and the plan is federally regulated). Approximately 65% of covered workers are in self-funded plans, which means most patients cannot rely on state step-therapy protections.

To determine if your plan is fully-insured or self-funded: look at your insurance card or Summary Plan Description. Self-funded plans often say "administered by [insurance company name]" — the employer funds the plan and the insurer only administers it.

Telehealth platforms that manage this for you

Several GLP-1 telehealth platforms handle the full PA and step therapy process as a service:

• Form Health ($99/month insured path): ABOM physician team manages all documentation and PA submission
• Calibrate ($199/month, 3-month minimum): 90-day PA guarantee with refund if unsuccessful
• Mochi Health ($79/month): PA support with compounded GLP-1 fallback during the wait
• Ro Body ($149/month): Insurance concierge service, 2–4 week PA timeline

Full comparison of these platforms at best insurance-friendly GLP-1 telehealth.

If you are going through your own prescriber, gather all documentation before the submission — not after the first denial. Every week of incomplete documentation is a week added to the access delay.